Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study evaluated the efficacy of adjuvant chemotherapy (AC) in patients with resected ampulla of Vater (AoV) carcinoma.Materials and Methods Data from 646 patients who underwent surgical resection at Asan Medical Center between 2000 and 2017 were retrospectively reviewed.Results The median age of the patients was 62 years, and 54.2% were male. Patients were classified into AC group (n=165, 25.5%) and no AC group (n=481, 74.5%). With a median follow-up duration of 88 months, in patients with stage I, II, III, median recurrence-free survival (RFS) was not reached, 44 months, and 15 months, respectively, and the median overall survival (OS) were not reached, 88 months and 35 months, respectively. Despite no statistical significance, RFS and OS were better in stage II patients with AC than in those without AC (median RFS, 151 months vs. 38 months; p=0.156 and median OS, 153 months vs. 74 months; p=0.299). In multivariate analysis for RFS and OS, TNM stage, R1 resection status, presence of lymphovascular invasion, and perineural invasion remained significant factors, whereas AC (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.54 to 1.00; p=0.052) was marginally related with RFS. After propensity score matching in only stage II/III patients, RFS and OS with AC were numerically longer than those without AC (HR, 0.80; 95% CI, 0.60 to 1.06; p=0.116 and HR, 0.77; 95% CI, 0.56 to 1.06; p=0.111).Conclusion AC with fluoropyrimidine did not improve survival of patients with resected AoV carcinoma. However, multivariate analysis with prognostic factors showed a marginally significant survival benefit with AC.
Abstract
Purpose This study evaluated the efficacy of adjuvant chemotherapy (AC) in patients with resected ampulla of Vater (AoV) carcinoma.Materials and Methods Data from 646 patients who underwent surgical resection at Asan Medical Center between 2000 and 2017 were retrospectively reviewed.Results The median age of the patients was 62 years, and 54.2% were male. Patients were classified into AC group (n=165, 25.5%) and no AC group (n=481, 74.5%). With a median follow-up duration of 88 months, in patients with stage I, II, III, median recurrence-free survival (RFS) was not reached, 44 months, and 15 months, respectively, and the median overall survival (OS) were not reached, 88 months and 35 months, respectively. Despite no statistical significance, RFS and OS were better in stage II patients with AC than in those without AC (median RFS, 151 months vs. 38 months; p=0.156 and median OS, 153 months vs. 74 months; p=0.299). In multivariate analysis for RFS and OS, TNM stage, R1 resection status, presence of lymphovascular invasion, and perineural invasion remained significant factors, whereas AC (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.54 to 1.00; p=0.052) was marginally related with RFS. After propensity score matching in only stage II/III patients, RFS and OS with AC were numerically longer than those without AC (HR, 0.80; 95% CI, 0.60 to 1.06; p=0.116 and HR, 0.77; 95% CI, 0.56 to 1.06; p=0.111).Conclusion AC with fluoropyrimidine did not improve survival of patients with resected AoV carcinoma. However, multivariate analysis with prognostic factors showed a marginally significant survival benefit with AC.
참고문헌 (25)
- Jin Z, "Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adeno-carcinoma : Mayo Clinic experience", Eur J Surg Oncol, 44, pp.677~683 (2018)
- Albores-Saavedra J, "Cancers of the ampulla of vater : demographics, morphology, and survival based on 5, 625 cases from the SEER program", J Surg Oncol, 100, pp.598~605 (2009)
- Hatzaras I, "Predictors of survival in periampullary cancers following pancreaticoduodenectomy", Ann Surg Oncol, 17, pp.991~997 (2010)
- Neoptolemos JP, "Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma : the ESPAC-3 periampullary cancer randomized trial", JAMA, 308, pp.147~156 (2012)
- Yeo CJ, "Periampullary adenocarcinoma : analysis of 5-year survivors", Ann Surg, 227, pp.821~831 (1998)
- Berberat PO, "An audit of outcomes of a series of periampullary carcinomas", Eur J Surg Oncol, 35, pp.187~191 (2009)
- O’Connell JB, "Survival after resection of ampullary carcinoma : a national population-based study", Ann Surg Oncol, 15, pp.1820~1827 (2008)
- Narang AK, "Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma : the Johns Hopkins HospitalMayo Clinic collaborative study", Radiat Oncol, 6, pp.126~ (2011)
- Kim K, "Role of adjuvant chemoradiotherapy for ampulla of Vater cancer", Int J Radiat Oncol Biol Phys, 75, pp.436~441 (2009)
- Zhou J, "Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater", Radiother Oncol, 92, pp.244~248 (2009)
- Ecker BL, "Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma", JAMA Surg, 154, pp.706~714 (2019)
- Kim HS, "Does adjuvant treatment improve prognosis after curative resection of ampulla of Vater carcinoma? A multicenter retrospective study", J Hepatobiliary Pancreat Sci, 27, pp.721~730 (2020)
- Bhatia S, "Adjuvant therapy for ampullary carcinomas : the Mayo Clinic experience", Int J Radiat Oncol Biol Phys, 66, pp.514~519 (2006)
- Lee JH, "Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas", Int J Radiat Oncol Biol Phys, 47, pp.945~953 (2000)
- Acharya A, "Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma", Br J Surg, 104, pp.814~822 (2017)
- Kwon J, "Survival benefit of adjuvant chemoradiotherapy in patients with ampulla of Vater cancer : a systematic review and meta-analysis", Ann Surg, 262, pp.47~52 (2015)
- Kimura W, "Incidence, sites of origin, and immunohistochemical and histochemical characteristics of atypical epithelium and minute carcinoma of the papilla of Vater", cancer, 61, pp.1394~1402 (1988)
- Ang DC, "The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater", Am J Surg Pathol, 38, pp.1371~1379 (2014)
- Okano K, "Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma", J Surg Oncol, 110, pp.156~162 (2014)
- Chang DK, "Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater", J Clin Oncol, 31, pp.1348~1356 (2013)
- Kim WS, "Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer", J Surg Oncol, 105, pp.266~272 (2012)
- Yachida S, "Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma", Cancer Cell, 29, pp.229~240 (2016)
- Andre T, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", N Engl J Med, 350, pp.2343~2351 (2004)
- Conroy T, "FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer", N Engl J Med, 379, pp.2395~2406 (2018)
- Ha HR, "Survival outcomes according to adjuvant treatment and prognostic factors including host immune markers in patients with curatively resected ampulla of Vater cancer", PLoS One, 11, pp.e0151406~ (2016)